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A B S T R A C T
Recent studies suggest that chronic inflammation is crucial in the development and progression of prostate cancer
(CaP). Interleukin-6 (IL-6) is a proinflammatory cytokine that plays an important role in intraprostatic inflammation
and thus carcinogenesis. The –174G>C polymorphism of IL-6 gene has been associated with high IL-6 producer pheno-
type and an increased risk for CaP. The aim of this study was to evaluate the association between the mentioned IL-6
polymorphism and CaP risk, as well as to compare the genotype frequency between the different tumour grades of CaP, in
population of Eastern Croatia. We analyzed the IL-6 polymorphism in 120 CaP patients and 120 controls with benign
prostatic hyperplasia (BPH). CaP patients and BPH controls did not statistically differ in studied IL-6 polymorphism.
Furthermore, high IL-6 producer genotypes (GG or GC) were more frequent in controls than in CaP group (86.7% vs
80.8%, respectively, p=0.147). Also, no statistically significant difference in IL-6 high and low producer genotype fre-
quency was noticed between well, moderately and poorly differentiated tumours. Our results, taken together with other
studies on the subject, suggest that IL-6 – 174 single nucleotide polymorphism (SNP) distribution may differ between
various ethnic groups and that a single cytokine gene polymorphism has probably just a minor effect on CaP susceptibil-
ity. Further studies should be performed to clarify the link between SNPs of different cytokines and the risk for CaP.
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Introduction
Although the etiology of prostate cancer (CaP) has
not yet been established, both genetic and environmental
factors appear to be involved. The lack of high-penetrant
susceptibility genes in CaP development1–3 and immigra-
tion studies4–7, which explain the rise in CaP risk when
immigrating from low to high incidence countries, all
support the role of environmental factors in CaP occu-
rence. Recent studies recognize infection, dietary derived
toxins, trauma and hormonal changes as prominent en-
vironmental factors relevant for the development of the
disease8–10. In response to all these events, intraprostatic
inflammation mostly develops as a necessary step to re-
move generated necrotic debris11. On the other hand, re-
active oxygen and nitrogen species, produced by phagocytic
cells, cause collateral damage in DNA, thus promoting
tumourigenesis9,12. Several works based on epidemiologi-
cal, histopathological and molecular pathological studies
have proposed a causative role of chronic inflammation
in the development and progression of many types of human
cancers, approximately 20% of all cancers8,9,13, including
CaP9,13–15. Inflammatory infiltrates and proliferative in-
flammatory atrophy (PIA) detected in CaP and benign
prostatic hyperplasia (BPH) specimens are histological
manifestation of inflammation and have been proposed
as a precursor in the development of CaP, highlighting an
inflammatory contribution to cancer occurence8,9.
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Entire process of inflammation is controlled by vari-
ous mediators, primarily cytokines and chemokines,
which are mostly produced and released locally, where
they mediate by autocrine and paracrine mechanisms11.
Among them, the strongest evidence for a role in pros-
tate carcinogenesis is found for Interleukin-6 (IL-6)16.
IL-6 is a pleiotropic proinflammatory cytokine synthe-
sized by many cell types involved in diverse biological
areas, including regulation of T- and B-cell function, Ig
secretion, acute phase inflammatory reactions and he-
matopoiesis11,17,18. It also acts as a paracrine growth
factor for some cancers14,17. Its uncontrolled production
may lead to chronic inflammation and thus could play an
important role in cancer risk11. There are several single
nucleotide polymorphisms (SNPs) in the IL-6 gene that
have been identified. It has been shown that the G>C
transition at position –174 in the promoter region of the
IL-6 gene appears to affect IL-6 transcription19 and the-
refore is associated with altered production of IL-620.
Accordingly, high producer genotypes (GG and GC) and
low producer genotype (CC) of IL-6 could be distingui-
shed19. Abovementioned polymorphism was found to be
associated with increased risk for several cancers21–23,
including CaP20,24. However, contoversial results concer-
ning association between IL-6 G-174C SNP and CaP are
thought to be influenced by ethnic differences.
The purpose of this study was to determine the IL-6
high and low producer genotype distribution in CaP
cases and BPH controls and to examine the association of
tested polymorphism with different tumour grades of
CaP.
Patients and Methods
120 CaP patients and 120 BPH controls treated at the
Clinic for Urology, University Hospital Centre Osijek
were included in this study, after giving informed con-
sent. Groups were age-matched. Detailed urological ex-
amination which included digital rectal examination
(DRE), prostate-specific antigen (PSA) testing and trans-
rectal or suprapubic ultrasonography was performed.
Clinical patient characteristics including family history
were obtained by a questionnaire. Furthermore, all sub-
jects who had serum PSA value greater than 4 ng/mL
and/or abnormal DRE were submitted to transrectal ul-
trasound-guided prostate needle biopsy, using a 12-core
protocol. Patients with histologically confirmed CaP on
prostate biopsy were divided into three subgroups ac-
cording to the Gleason score (GS) (well differentiated
(GS<6), moderately differentiated (GS 6 and 3+4=7)
and poorly differentiated tumors with GS ³ 4+3=7). Pa-
tients in the Control group were selected according to the
histological finding of BPH, obtained by prostate biopsy,
transuretral resection of the prostate or by open prosta-
tectomy. Those patients who had pathological finding of
atypical small acinar proliferation (ASAP) or (before
2009.) high-grade prostatic intraepithelial neoplasia
(high-grade PIN) on prostate biopsy were subjected to
another biopsy and later classified, according to the re-
sults, to either CaP or BPH group.
To determine the IL-6 –174 SNP, genomic DNA was
extracted from 200 ml ethylenediaminetetraacetic acid
(EDTA) whole blood using High Pure polymerase chain
reaction (PCR) Template Preparation Kit (Roche Diag-
nostics, Mannheim, Germany) following the manufac-
turer’s instructions. IL-6-174 G/C gene polymorphism
was assessed by real-time PCR method with melting
curve analysis. In the reaction volume of 10 ìL approxi-
mately 40 ng of template DNA were amplified in the
presence of 0.5 ìM primers each (sense 5’-TTA CTC TTT
GTC AAG ACA TGC CA-3’, antisense 5’-ATG AGC CTC
AGA CAT CTC CAG-3’), 0.2 ìM probes each (anchor
5’-CTA AGC TGC ACT TTT CCC CCT AGT-fluores-
cein-3’, sensor 5’-LCRed640-GTG TCT TGC GAT GCT
AAA GGA-P-3’), 2.5 mM MgCl2 and 1x LC DNA Master
Hybridization Probes buffer (Roche Diagnostics). PCR
reactions were performed using LightCycler Instrument
(Roche Diagnostics) according to the conditions descri-
bed previously25. To confirm the results of genotyping,
20% of the study samples were randomly selected for
genotyping again and the results were 100% congruent.
Descriptive statistical analysis was performed with
SPSS 10.0 statistical program (SPSS Inc., Chicago, Ill,
USA); Kolmogorov-Smirnov test was used to determine
the differences between the groups and Fisher Exact test
for comparing different variables between the groups. P
<0.05 was considered statistically significant.
Results
There were 120 CaP patients and 120 BPH controls
included in this study. Median age of all patients was 68
years (range 42–84). Two studied groups were age-




All patients CaP group BPH group CaP vs BPH
No. of patients 240 120 120
Median (range) age in years 68 (42–84) 68 (46–84) 68 (42–79) p=0.564
Median (range) PSA in ng/mL 8.1 (0.57–3346) 12.4 (2.10–3346) 6.81 (0.57–28) p=0.0001
Positive family history (%) 17 (7.1) 10 (8.3) 7 (5.8) p=0.308
CaP – prostate cancer; BPH – benign prostatic hyperplasia; PSA – prostate-specific antigen; p<0.05 considered statistically significant
-matched (p=0.564). CaP group had, as expected, signifi-
cantly higher median PSA values than control group
(12.40 vs 6.81 ng/mL, with p=0.0001). Positive family
history of CaP was more common in CaP (8.3%) than in
control group (5.8%), but this was not statistically signif-
icant (p=0.308). Patient characteristics for CaP and
BPH groups are listed in Table 1.
Out of 120 CaP subjects 10 had well, 69 moderately
and 41 poorly differentiated tumors. Most common GS
was 6(3+3) in 37.5% of the patients. The three sub-
groups of CaP patients did not differ in family history,
but we did find significant difference in age and PSA
value. The characteristics and comparison of the three
CaP subgroups are listed in Table 2.
The IL-6 high producer genotypes (GG or GC) were
more frequent in patients with BPH than in CaP group
(86.7 vs 80.8%, respectively), but the difference was not
statistically significant (p=0.147) and odds ratio (OR) for
BPH was 1.54 (95% CI 0.77–3.09). Analysis of genotype
frequency within CaP subgroups showed no statistically
significant difference between IL-6 high and low produ-
cer genotypes (p=0.633, p=0.497 and p=0.256 for well vs
moderately, well vs poorly and moderately vs poorly
differentiated tumors). IL-6 high producer genotype fre-
quency for all groups is listed in Table 3.
Discussion
The objective of our research was to investigate whe-
ther there was difference in IL-6 cytokine gene polymor-
phism between CaP patients and controls with BPH, as
well as between the CaP subgroups, which were divided
according to tumour differentiation.
It was previously shown that IL-6 has a role in the
development and progression of several types of human
cancers and inflammatory diseases26,27. Because of the
various functions of IL-6 it may play different roles in
CaP natural history28, acting as a paracrine growth inhi-
bitor in hormone dependent cell lines29 and an autocrine
and paracrine growth factor in hormone refractory hu-
man prostate cancer cell lines30. The G>C polymorphism
at position –174 in the promoter of the IL-6 gene has
been associated with the aggressiveness and recurrence
of CaP20 and serum IL-6 levels were significantly ele-
vated in hormone-refractory prostate cancer patients
compared to controls31,32, as well as in patients with
clinically evident CaP metastases33,34.
As it was mentioned before, the G>C transition poly-
morphism at position –174 in the promoter region of the
IL-6 gene is associated with the difference in the produc-
tion of IL-6. Individuals can accordingly be classified into
high (genotypes GG and GC) and low (genotype CC) IL-6
producers19. The reason we included the abovementio-
ned classification in our study was because we wanted to
correlate genotype (GG/GC and CC) with phenotype
(high and low producer) of IL-6 cytokine.
In our analysis, CaP patients and age-matched con-
trols with BPH did not statistically differ in studied IL-6
polymorphism. Furthermore, high IL-6 producer geno-
types (GG or GC) were more frequent in controls than in
CaP group (86.7% vs 80.8%, respectively, Table 3). Odds
ratio for BPH patient to be high IL-6 producer was 1.54,
with 95% CI 0.77–3.09.
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TABLE 2
CHARACTERISTICS AND COMPARISON OF CaP SUBGROUPS







No. (%) of patients 10 (8.3) 69 (57.5) 41 (34.2)
Median (range) age in years 65 (52–74) 67 (46–83) 72 (48–84) p=0.779 p=0.154 p=0.047
Median (range) PSA in ng/mL 8.05 (4–41.6) 10.3 (2.4–112) 28 (2.1–3346) p=0.188 p=0.0001 p=0.0001
Positive family history (%) 1 (10) 7 (10.14) 2 (4.88) p=0.680 p=0.488 p=0.277
Subgroup A – Well differentiated tumors (GS<6); Subgroup B – Moderately differentiated tumors (GS 6 and 3+4=7); Subgroup C –
Poorly differentiated tumors (GS ³ 4+3=7); PSA – prostate-specific antigen; p<0.05 considered statistically significant
TABLE 3
IL-6 HIGH PRODUCER GENOTYPE FREQUENCY FOR ALL GROUPS
BPH group CaP group BPH vs CaP
No (%) of patients 104/120 (86.7) 97/120 (80.8) p=0.147
Subgroup A Subgroup B Subgroup C A vs B A vs C B vs C
No (%) of patients 8/10 (80) 54/69 (78.3) 35/41 (85.4) p=0.633 p=0.497 p=0.256
BPH – benign prostatic hyperplasia; CaP – prostate cancer; Subgroup A – Well differentiated tumors (GS<6); Subgroup B – Moder-
ately differentiated tumors (GS 6 and 3+4=7); Subgroup C – Poorly differentiated tumors (GS ³ 4+3=7); p<0.05 considered statisti-
cally significant
In dividing CaP patients into three subgroups based
on the tumour differentiation we analyzed and compared
the studied IL-6 polymorphism between more and less
aggressive prostate tumours. Again, no statistically sig-
nificant difference in IL-6 high and low producer geno-
type frequency was noticed between well, moderately
and poorly differentiated tumors (Table 3).
In a study by Tan and coworkers20 a strong associa-
tion between –174 G>C polymorphism and GS of the
CaP patients was found. The authors also found different
distributions of these genotypes between stages T3–T4
and T1–T2 of the tumours. In that retrospective study
the analysis included patients treated with radical pros-
tatectomy only and the comparison was made between
GC/CC and GG genotypes. This is contrary to our analy-
sis where GG/GC (high producer) and CC (low producer)
were compared. Furthermore, the definition of well,
moderately and poorly differentiated tumors differed in
the two studies, so the comparison with the abovemen-
tioned study can not be made.
Kesarwani24 and others analyzed Interleukin-4 (IL-4)
and IL-6 (–174 G/C) gene polymorphisms in 200 controls
and 200 cases of CaP in North Indian population and
found no significant association with the risk of CaP.
However, they noticed a twofold risk for progression to
bone metastasis in CaP patients, but no association with
GS was seen.
When studying the association between the SNPs in
–174G/C and –634C/G of interleukin-6 promoter region
and CaP in the population of Han people in Hubei region,
Bao and coworkers35 concluded that no SNP at position
–174 was found (no CG and CC genotypes were observed).
The aforementioned studies and contradictory results
clearly imply the ethnic background and distribution of
IL-6 polymorphisms. Ethnicity appears to also influence
the frequency and distribution of the polymorphisms of
other cytokines, which altogether makes it almost impos-
sible to make a global cytokine gene pattern. Our study, a
part of the project »Immunological factors in develop-
ment and progression of prostate cancer«, analyzed the
difference in IL-6 cytokine gene polymorphism between
CaP patients and controls with BPH, with final goal to
map polymorphisms of genes for IL-6, Tumor necrosis
factor-alpha (TNFá), Interleukin-10 (IL-10), Transfor-
ming growth factor beta (TGF-â), Interferon-gamma
(IFN-ã) and Toll-like receptor 4 (TLR 4) in CaP patients
of our population. So far such results have not been
published for Croatian population.
In conclusion, our study showed that there were no
significant differences in the distribution of the IL-6-174
SNP genotypes between CaP and BPH control subjects
in population of Eastern Croatia. These findings, taken
together with contradictory results of other studies im-
ply the ethnical dependency of the IL-6-174 polymor-
phism. Other possible explanation is that a single cyto-
kine gene polymorphism has probably just a minor effect
on CaP susceptibility. Combinations and interactions of
SNPs of different cytokines have a greater impact on
CaP development and they might modify the risk for CaP.
Further studies concerning SNPs of different cytokines
and susceptibility to CaP should be performed in order to
define their true importance in the development and
progression of the disease.
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POLIMORFIZAM INTERLEUKINA-6 I RIZIK OD KARCINOMA PROSTATE
U POPULACIJI ISTO^NE HRVATSKE
S A @ E T A K
Novija istra`ivanja navode kroni~nu upalu kao klju~ni ~imbenik u nastanku i progresiji karcinoma prostate (CaP).
Interleukin-6 (IL-6) je proinflamatorni citokin koji ima va`nu ulogu u upali prostate, a prema tome i u karcinogenezi.
–147G>C polimorfizam IL-6 gena se povezuje s fenotipom visoke produkcije IL-6 i pove}anim rizikom za CaP. Cilj ovog
istra`ivanja bio je ispitati povezanost izme|u navedenog IL-6 polimorfizma i rizika za razvoj CaP, kao i usporediti
frekvenciju genotipova izme|u razli~itih stadija karcinoma prostate, u populaciji Isto~ne Hrvatske. Ispitali smo poli-
morfizam IL-6 u 120 pacijenata s CaP i 120 kontrolnih subjekata s benignom hiperplazijom prostate (BPH). Pacijenti s
CaP se u ispitivanom polimorfizmu IL-6 nisu statisti~ki razlikovali od kontrola s BPH. [tovi{e, genotipovi visoke pro-
dukcije IL-6 (GG ili GC) bili su u~estaliji u kontrolnoj grupi nego u grupi s CaP (86,7% naspram 80,8%, p=0,147). Osim
toga, zna~ajna razlika u raspodjeli genotipova visoke i niske produkcije nije na|ena niti izme|u dobro, srednje i slabo
diferenciranih tumora. Na{i rezultati, ako se uzmu u obzir i ostale studije o istoj temi, navode na zaklju~ak da bi se
raspodjela polimorfizma IL-6-174 mogla razlikovati me|u razli~itim etni~kim skupinama i da polimorfizam jednog nu-
kleotida gena za citokine vjerojatno ima samo manji utjecaj na podlo`nost razvoja CaP. Potrebna su daljnja istra`ivanja
kako bi se pojasnila poveznica izme|u polimorfizama gena razli~itih citokina i rizika za CaP.
S. Mandi} et al.: Interleukin-6 Polymorphism and Prostate Cancer, Coll. Antropol. 37 (2013) 3: 907–911
911
